Supplementary figure 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Key Points

• Nrf2 hyperactivation leads to increased radiotherapy resistance in patients with head and neck squamous cell carcinoma, affecting treatment outcomes.
• The presence of specific mutations was noted in patients with HNSCC, indicating a complex interaction with antitumor immunity.
• The analysis included evaluations of mutation status and its co-occurrence, contributing to understanding resistance mechanisms.
• Findings highlight the importance of nrf2 in shaping tumor responses to therapy, calling for further investigation into targeted approaches.